Shan Lu

Summary

Affiliation: University of Massachusetts Medical School
Country: USA

Publications

  1. ncbi Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Vaccine 26:1098-110. 2008
  2. ncbi Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Vaccine 26:3947-57. 2008
  3. ncbi Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates
    Michael Vaine
    Room 304, LRB, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    J Virol 85:4927-36. 2011
  4. ncbi Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection
    Jun Li
    Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China
    Virol J 8:199. 2011
  5. ncbi Technical transformation of biodefense vaccines
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Vaccine 27:D8-D15. 2009
  6. ncbi Combination DNA plus protein HIV vaccines
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Springer Semin Immunopathol 28:255-65. 2006
  7. ncbi Polyvalent AIDS vaccines
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Curr HIV Res 8:622-9. 2010
  8. ncbi Current progress of DNA vaccine studies in humans
    Shan Lu
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, LRB 304, Worcester, MA 01605, USA
    Expert Rev Vaccines 7:175-91. 2008
  9. ncbi Heterologous prime-boost vaccination
    Shan Lu
    China US Vaccine Research Center and Department of Infectious Diseases, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
    Curr Opin Immunol 21:346-51. 2009
  10. ncbi Immunogenicity of DNA vaccines in humans: it takes two to tango
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Hum Vaccin 4:449-52. 2008

Research Grants

  1. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2010
  2. Multi-gene plague vaccine with expanded protection
    Shan Lu; Fiscal Year: 2004
  3. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2009

Collaborators

Detail Information

Publications66

  1. ncbi Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Vaccine 26:1098-110. 2008
    ....
  2. ncbi Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Vaccine 26:3947-57. 2008
    ....
  3. ncbi Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates
    Michael Vaine
    Room 304, LRB, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    J Virol 85:4927-36. 2011
    ..This progress will facilitate the rational design of effective HIV-1 vaccine formulations with optimal Env antigens...
  4. ncbi Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection
    Jun Li
    Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China
    Virol J 8:199. 2011
    ....
  5. ncbi Technical transformation of biodefense vaccines
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Vaccine 27:D8-D15. 2009
    ....
  6. ncbi Combination DNA plus protein HIV vaccines
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Springer Semin Immunopathol 28:255-65. 2006
    ....
  7. ncbi Polyvalent AIDS vaccines
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Curr HIV Res 8:622-9. 2010
    ..Results summarized in this review provide a clear indication that the polyvalent approach is a viable one for the future development of an effective HIV vaccine...
  8. ncbi Current progress of DNA vaccine studies in humans
    Shan Lu
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, LRB 304, Worcester, MA 01605, USA
    Expert Rev Vaccines 7:175-91. 2008
    ..The majority of these trials are designed to test candidate vaccines against several major human pathogens and the remaining studies tested the immunogenicity of therapeutic vaccines against cancer...
  9. ncbi Heterologous prime-boost vaccination
    Shan Lu
    China US Vaccine Research Center and Department of Infectious Diseases, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
    Curr Opin Immunol 21:346-51. 2009
    ..Heterologous prime-boost represents a new way of immunization and will stimulate better understanding on the immunological basis of vaccines...
  10. ncbi Immunogenicity of DNA vaccines in humans: it takes two to tango
    Shan Lu
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Hum Vaccin 4:449-52. 2008
    ....
  11. ncbi Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)
    Te-hui W Chou
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, USA
    Virology 334:134-43. 2005
    ..The availability of this panel of mAbs also provided potentially useful agents with applications in therapy, diagnosis, and basic research of SARS-CoV...
  12. ncbi Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605 2397, USA
    Vaccine 26:1664-74. 2008
    ..These results demonstrate that DNA immunization is effective in screening, optimizing and comparing optimal antigen designs and immunogenicity of candidate antigens for the development of a subunit-based plague vaccine...
  13. ncbi Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens
    Pavlo Sakhatskyy
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Virology 371:98-107. 2008
    ..Vaccinated mice were protected from intraperitoneal and intranasal challenges with VACV. These results suggest the feasibility of a subunit smallpox vaccine based on VARV antigen sequences to induce immunity against poxvirus infection...
  14. ncbi Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1
    Shixia Wang
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, USA
    J Virol 79:7933-7. 2005
    ....
  15. ncbi Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates
    Zuhu Huang
    Department of Infectious Diseases, Nanjing Medical University, Nanjing, China
    Curr HIV Res 6:296-305. 2008
    ..These data provide further evidence on the complexity of primary HIV-1 Env antigens and offers new insight into the mechanisms that HIV-1 uses to escape protective immune responses...
  16. ncbi Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
    Michael Vaine
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Virol 82:7369-78. 2008
    ....
  17. ncbi Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605 2397, United States
    Vaccine 28:2011-9. 2010
    ..Most importantly, proper antigen engineering to produce optimal antigen gene inserts in DNA vaccines can clearly play a major role in the future designs of a wide range of DNA vaccines...
  18. ncbi Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses
    Shixia Wang
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Vaccine 26:3626-33. 2008
    ..This finding justifies further investigation of HA DNA vaccines as a priming immunogen for the next generation of vaccines against seasonal or pandemic influenza virus infections...
  19. ncbi Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses
    Shixia Wang
    China US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
    PLoS ONE 6:e28757. 2011
    ..Data presented in this report support the development of a polyvalent DNA vaccine strategy against the threat of a potential H5N1 influenza pandemic...
  20. ncbi Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes
    Ussama M Abdel-Motal
    Department of Surgery, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Vaccine 28:1758-65. 2010
    ..This strategy of anti-Gal mediated targeting to APC may be used for production of effective HIV-1 vaccines comprised of various viral proteins fused to gp120...
  21. ncbi Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity
    Michael Vaine
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, United States
    Vaccine 28:2999-3007. 2010
    ....
  22. ncbi Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen
    Pavlo Sakhatskyy
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Rm 304, LRB, 364 Plantation Street, Worcester, MA 01605, USA
    Virology 355:164-74. 2006
    ..Therefore, D8 is an excellent candidate antigen to be included in the final polyvalent subunit-based poxvirus vaccines...
  23. ncbi Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Virology 350:34-47. 2006
    ....
  24. ncbi DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates
    Siyuan Shen
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Vaccine 25:3319-27. 2007
    ..DNA vaccination is an effective approach to express the gM/gN antigen complex in vivo without the need to express and purify these highly insoluble and structurally complicated antigens...
  25. ncbi Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine
    Guohong Ge
    Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
    PLoS ONE 7:e41573. 2012
    ....
  26. ncbi Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer
    Leslie Oleksowicz
    Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Prostate 72:1140-9. 2012
    ..The current study further explored the underlying mechanism of sPLA2-IIa overexpression and the potential role of sPLA2-IIa as a prostate cancer biomarker...
  27. ncbi Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1)
    Michael Vaine
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    BioDrugs 23:137-53. 2009
    ....
  28. ncbi The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
    Jeffrey S Kennedy
    Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, MA, USA
    Vaccine 26:4420-4. 2008
    ..Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine...
  29. ncbi Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA
    Vaccine 24:4531-40. 2006
    ....
  30. ncbi EV71: an emerging infectious disease vaccine target in the Far East?
    Juan Xu
    Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210030, China
    Vaccine 28:3516-21. 2010
    ....
  31. ncbi Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies
    Michael Vaine
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
    PLoS ONE 5:e13916. 2010
    ....
  32. ncbi RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions
    E Xiaofei
    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Virol 86:5660-73. 2012
    ..Together, these findings suggest that siRNAs targeting exon 3 of the major IE genes or the UL54-57 transcripts be further studied for their potential development into anti-HCMV therapeutics...
  33. ncbi A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Vaccine 22:3348-57. 2004
    ..These results support that optimized DNA vaccines have the potential to protect against bacterial pathogens than is generally recognized...
  34. ncbi Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV)
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, United States
    J Immunol Methods 301:21-30. 2005
    ..In this report, we described the utility of these two new neutralization assays in measuring the neutralizing activities against SCV infection from rabbit sera immunized with various forms of spike protein of SCV...
  35. ncbi A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates
    Zheng Wang
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Virol Methods 171:183-9. 2011
    ..This system is useful for testing the neutralizing sensitivity of partial env gene products frequently identified in viral quasi species in patients infected with HIV or when only partial gp120 gene products are available...
  36. ncbi Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer
    Zhongyun Dong
    Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Oncol Rep 25:1511-6. 2011
    ..These data revealed that Vav3 overexpression as an additional underlying mechanism contributes to elevated sPLA2-IIa expression in prostate cancer...
  37. ncbi Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
    Anju Bansal
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Virol 82:6458-69. 2008
    ..These findings demonstrate that the route and dose of DNA vaccines significantly impact the quality of immune responses, yielding important information for future vaccine design...
  38. ncbi Expression and immunogenicity of novel subunit enterovirus 71 VP1 antigens
    Juan Xu
    China US Vaccine Research Center, The First Affiliated Hospital, Nanjing Medical University, China
    Biochem Biophys Res Commun 420:755-61. 2012
    ..Data presented in the current report revealed novel pathways to optimize the design of VP1 antigen-based EV71 vaccines...
  39. ncbi Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen
    Meilong Shen
    Department of Infectious Diseases, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
    Vaccine 28:7288-96. 2010
    ....
  40. ncbi Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera
    Guifang Xu
    Department of Infectious Diseases, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
    Vaccine 27:3821-30. 2009
    ....
  41. ncbi The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen
    Yiping Xing
    Department of Infectious Diseases, Nanjing Medical University, and China US Vaccine Research Center, Jiangsu Province Hospital, Nanjing 210029, China
    Vaccine 26:5145-52. 2008
    ..This finding provides important direction to the development of S DNA vaccines to elicit the optimal and balanced antibody and cell-mediated immune responses to treat people with HBV chronic infections...
  42. ncbi Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes
    Ussama Abdel-Motal
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, LRB, Worcester, 01605, USA
    J Virol 80:6943-51. 2006
    ..It is suggested that gp120(alphagal) can serve as a platform for anti-Gal-mediated targeting of additional vaccinating HIV proteins fused to gp120(alphagal), thereby creating effective prophylactic vaccines...
  43. ncbi Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines
    Shixia Wang
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605-2397, USA
    J Virol 80:11628-37. 2006
    ..Our findings will have an important impact on future subunit-based flu vaccine development...
  44. ncbi Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation St, Lazare Research Building, Worcester, MA 01605 2397, USA
    J Virol 79:1906-10. 2005
    ..Two neutralizing domains were identified on the S protein, one at the N terminus (Ser12-Thr535) and the other near the C terminus (Arg797-Ile1192)...
  45. ncbi Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model
    Fangjun Liu
    Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA
    Vaccine 22:1764-72. 2004
    ..However, for both humoral and CMI responses, there were no synergistic effects when the combination of codon optimization and C3d fusion was employed...
  46. ncbi Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge
    Shixia Wang
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Vaccine 29:6802-9. 2011
    ..pestis in higher animal species or humans...
  47. ncbi Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism
    Olivia O'Connell
    Program in Molecular Medicine and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Virol 87:187-98. 2013
    ..We present a model where the efficiency of bridging-sheet recruitment by CD4 is a major determinant of HIV-1 R5 envelope sensitivity to soluble CD4 and macrophage tropism...
  48. ncbi Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis
    Kimberly Pouliot
    Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Infect Immun 75:3571-80. 2007
    ..Taken together, our data indicate that the most abundant molecular species of Y. pestis LcrV do not efficiently activate TLR2-signaling and that TLR2-mediated immunomodulation is unlikely to play a significant role in plague...
  49. ncbi Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization
    John E Herrmann
    Antibody Science, Inc, 80 Webster Street, Worcester, MA 01603, USA
    Vaccine 24:5872-80. 2006
    ..anthracis (Sterne strain) spores. The high titer antisera we produced will enable an immunization strategy to supplement antibiotic therapy for improving the survival of patients with anthrax...
  50. ncbi Clostridium difficile infections in China
    Ke Jin
    Department of Infectious Diseases, Jiangsu Province Key Laboratory in Infectious Diseases, China US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
    J Biomed Res 24:411-6. 2010
    ..Such information is ultimately valuable to develop appropriate strategies to prevent C. difficile infection and the vast negative impact of such infections in China and other developing countries...
  51. ncbi Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer
    Zhongyun Dong
    Department of Medicine, University of Cincinnati College of Medicine, 2120 East Galbraith Road, Cincinnati, OH 45237 0507, USA
    Carcinogenesis 31:1948-55. 2010
    ..Given that sPLA2-IIa overexpression is associated with prostate development and progression, serum sPLA2-IIa may serve as a prognostic biomarker for prostate cancer and a potential surrogate prostate biomarker indicative of tumor burden...
  52. ncbi C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness
    John Patrick Haran
    Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Am J Emerg Med 31:137-44. 2013
    ..We hypothesize that C-reactive protein (CRP) levels among patients with ILI diagnosed with a bacterial infection will be higher than patients diagnosed with an influenza or another viral infection...
  53. ncbi Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
    Shiyang Pan
    Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
    Biomed Pharmacother 66:131-7. 2012
    ..The quantification of plasma DNA is a sensitive indicator of chemotherapeutic efficacy in advanced lung cancer patients, and it can be useful in predicting response to therapy and guiding medication...
  54. ncbi Delivery of DNA to skin by particle bombardment
    Shixia Wang
    Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Methods Mol Biol 245:185-96. 2004
  55. ncbi An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus
    Xiaofei E
    Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
    PLoS Pathog 7:e1001342. 2011
    ..Given that E2F activity is often deregulated by infection with DNA viruses, these observations raise the possibility that an E2F1-mediated mechanism of DDR activation may be conserved among DNA viruses...
  56. ncbi Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype
    Ranajit Pal
    Department of Cell Biology, Advanced BioScience Laboratories, Kensington, MD 20895, USA
    Virology 348:341-53. 2006
    ....
  57. ncbi Human versus HIV: round 2 defeat in AIDS vaccine development
    Shan Lu
    Expert Rev Vaccines 7:151-3. 2008
  58. ncbi Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine
    Anthony D Cristillo
    Advanced BioScience Laboratories, Department of Cell Biology, 5510 Nicholson Lane, Kensington, MD 20895, USA
    Virology 346:151-68. 2006
    ....
  59. ncbi Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits
    Ranajit Pal
    Department of Cell Biology, Advanced BioScience Laboratories, 5510 Nicholson Lane, Kensington, MD 20895, USA
    Vaccine 24:1225-34. 2006
    ..These studies demonstrate that a novel polyvalent DNA prime/protein boost vaccine lacks signs of toxicity and DNA integration in a rabbit model, and immunogenicity and toxicology data support clinical testing of the vaccine in humans...
  60. ncbi Application of the polyvalent approach to HIV-1 vaccine development
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Curr Drug Targets Infect Disord 5:143-56. 2005
    ..Information presented in this review highlights the potential and importance of the polyvalent vaccine approach for the future development of an effective HIV-1 vaccine...
  61. ncbi Novel DNA vaccine based on hepatitis B virus core gene induces specific immune responses in Balb/c mice
    Yi Ping Xing
    Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China
    World J Gastroenterol 11:4583-6. 2005
    ..To investigate the immunogenicity of a novel DNA vaccine, pSW3891/HBc, based on HBV core gene in Balb/c mice...
  62. ncbi Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate
    Ranajit Pal
    Advanced BioScience Laboratories, Kensington, MD 20895, USA
    J Med Primatol 34:226-36. 2005
    ....
  63. ncbi [Immunogenicity of new DNA vaccine encoding for hepatitis B virus core antigen]
    Yi-ping Xing
    Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
    Zhonghua Gan Zang Bing Za Zhi 12:338-40. 2004
    ..Mice immunized with pSW3891/HBc showed strong anti-HBc response and specific high cytotoxicity of CTL. CONCLUSION: pSW3891/HBc induced significantly humoral and cellular immune responses in Balb/c mice...
  64. ncbi The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods
    Shixia Wang
    China US Vaccine Research Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
    Vaccine 26:2100-10. 2008
    ..These findings provide important information for the further selection and optimization of DNA vaccine delivery methods for human applications...
  65. ncbi Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer
    Zhongyun Dong
    Department of Pathology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, Ohio 45267, USA
    Mol Endocrinol 20:2315-25. 2006
    ..These findings suggest that Vav3 overexpression may be involved in prostate cancer development and progression...
  66. ncbi Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope
    Susan Zolla-Pazner
    New York Veterans Affairs Medical Center, New York, NY 10010, USA
    Virology 372:233-46. 2008
    ..Neutralizing activity was primarily due to V3-specific Abs. The results demonstrate that the immune response can be focused on a neutralizing epitope and show that the anti-V3 Abs induced recognize a diverse set of V3 loops...

Research Grants8

  1. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2010
    ..This will allows us to effectively screen a large number of unique primary Env antigens to formulate the effective polyvalent HIV vaccines for the next phase of clinical testing. ..
  2. Multi-gene plague vaccine with expanded protection
    Shan Lu; Fiscal Year: 2004
    ..This project will employ the most advanced DNA immunization technology in combination with small-scale protein production to quickly develop potential subunit-based plague vaccine products. ..
  3. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2009
    ..This will allows us to effectively screen a large number of unique primary Env antigens to formulate the effective polyvalent HIV vaccines for the next phase of clinical testing. ..